home / stock / cybn / cybn articles

CYBN Articles, Cybin Inc.

Stock Information
Company Name: Cybin Inc.
Stock Symbol: CYBN
Market: NYSE
Website: cybin.com
Menu
CYBN CYBN Quote CYBN Short CYBN News CYBN Articles CYBN Message Board
Get CYBN Alerts

News, Short Squeeze, Breakout and More Instantly...
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More | Benzinga

As the premier gathering of top entrepreneurs and investors took place on Monday in New Jersey, we thought it would be a good time to scroll throug...
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon | Benzinga

Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate ...

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More | Benzinga

Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024. See prev...

Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss | Benzinga

The TDR Three Key Takeaways: Positive Clinical Progress: Cybin Inc. has reported significant advancements in its clinical programs, notably achiev...
FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxiety | Benzinga

Psychedelics biotech Cybin Inc. (NYSE:CYBN) has received clearance from the Food and Drug Administration (FDA) on its Investigational New Drug (IND...

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More | Benzinga

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.&nbs...

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More | Benzinga

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond | Benzinga

The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...

Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results | Benzinga

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenou...

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD | Benzinga

A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit...
Next 10